It is probably worthwhile having a barbell approach in the pharma sector with mainly largecap names and maybe one or two smaller ones as well, says the Global Investment Strategist.
How are you looking at the overall sentiment for the emerging markets and in particular for India? The mid and the smallcaps too have been outperforming.
It is a fascinating time. Markets are very strong globally. The dollar is fairly weak and that is usually a fairly positive outlook for the emerging markets. Like a lot of other global markets, the emerging markets too have pushed up, including India with gains year to date. Broadly speaking, we are in an interesting phase. We are approaching the US elections. Geopolitical concerns are re-emerging or simply not going